-
123I-β-甲基-p-碘苯基十五烷酸(123I-β-methyl-p-iodophenyl pentadecanoic acid,123I-BMIPP)是最新研究的一种游离脂肪酸放射性核素显像剂,它在心肌中的代谢比较慢,因此适合于SPECT的分子成像[1]。123I-BMIPP显像可以反映心肌恢复灌注前严重的缺血,因此被称为缺血性记忆[2]。这种心血管分子显像技术可以评估心脏疾病的严重程度及预后,如心力衰竭、严重的冠状动脉疾病和心肌病等,而且这种技术也是评估心脏疾病治疗方法和治疗效果的重要方法。因此,分子显像技术有望在各种心血管疾病的临床治疗决策中使用[3]。
123I-β-甲基-p-碘苯基十五烷酸心肌显像研究进展
Advances in β-methyl-p-iodophenyl pentadecanoic acid myocardial imaging
-
摘要: 脂肪酸代谢是心肌中最高效的供能方式。脂肪酸代谢水平的改变被认为是心肌缺血和心肌损伤最敏感的指标。心肌缺血后,尽管血液灌注已恢复,但脂肪酸代谢的长期抑制还会持续,这就是所谓的代谢顿抑或缺血记忆。用放射性核素标记β-甲基-p-碘苯基十五烷酸(BMIPP)SPECT评估脂肪酸的代谢,对早期发现心肌缺血,评估缺血性冠状动脉疾病及心肌病的严重性及预后有重要的作用。该文对123I-BMIPP心肌显像的近期研究进展进行综述。Abstract: Fatty acid metabolism is the most efficient mode of myocardial energy production. Alter- ation of fatty acid metabolism is considered to be a sensitive marker of ischaemia and myocardial damage. After myocardial ischemia, prolonged suppression of fatty acid metabolism may persist despite restoration of blood flow, which is called metabolic stunning or ischemia memory. Assessment of fatty acid metabolism by radionu-clide labeled β-methyl-p-iodophenyl pentadecanoic acid(BMIPP) SPECT plays a potential role in the early detection of myocardial ischaemia and the assessment of the severity of ischaemic coronary artery disease and myocardial disease. This article describes recent advances in 123I-BMIPP myocardial imaging.
-
Key words:
- Myocardial ischemia /
- Fatty acids /
- Tomography /
- emission-computed /
- single-photon
-
[1] Biswas SK, Sarai M, Hishida H, et al. 123I-BMIPP fatty acid analogue imaging is a novel diagnostic and prognostic approach following acute myocardial infarction. Singapore Med J, 2009, 50(10): 943-948. [2] Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol, 2011, 18(1): 135-143. doi: 10.1007/s12350-010-9305-4 [3] Wu JC, Bengel FM, Gambhir SS. Cardiovascular molecular imaging. Radiology, 2007, 244(2): 337-355. [4] Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis, 1981, 23(5): 321-336. [5] Schwaiger M, Neese RA, Araujo L, et al. Sustained nonoxidative glucose utilization and depletion of glycogen in reperfused canine myocardium. J Am Coll Cardiol, 1989, 13(3): 745-754. doi: 10.1016/0735-1097(89)90621-9 [6] Bergmann SR, Lerch RA, Fox KA, et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med, 1982, 73(4): 573-581. doi: 10.1016/0002-9343(82)90338-2 [7] Schwaiger M, Schelbert HR, Ellison D, et al. Sustained regional abnormalities in cardiac metabolism after transient ischemia in the chronic dog model. J Am Coll Cardiol, 1985, 6(2): 336-347. doi: 10.1016/S0735-1097(85)80169-8 [8] Dilsizian V, Bateman TM, Bergmann SR, et al. Metabolic imaging with beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation, 2005, 112(14): 2169-2174. doi: 10.1161/CIRCULATIONAHA.104.530428 [9] Tamaki N, Morita K, Kawai Y. The Japanese experience with metabolic imaging in the clinical setting. J Nucl Cardiol. 2007, 14Suppl3: S145-152. [10] Kawai Y, Tsukamoto E, Nozaki Y, et al. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol, 2001, 38(7): 1888-1894. doi: 10.1016/S0735-1097(01)01634-5 [11] Watanabe K, Takahashi T, Miyajima S, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med, 2002, 43(11): 1476-1481. [12] Inaba Y, Bergmann SR. Diagnostic accuracy of beta-methyl-para-[123I]-iodophenyl-pentadecanoic acid(BMIPP) imaging: a metaanaly-sis. J Nucl Cardiol, 2008, 15(3): 345-352. doi: 10.1016/j.nuclcard.2008.02.019 [13] Yamabe H, Fujiwara S, Rin K, et al. Resting 123I-BMIPP scintigraphy for detection of organic coronary stenosis and therapeutic outcome in patients with chest pain. Ann Nucl Med, 2000, 14(3): 187-192. [14] Kontos MC, Dilsizian V, Weiland F, et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes. J Am Coll Cardiol, 2010, 56(4): 290-299. doi: 10.1016/j.jacc.2010.03.045 [15] Hambÿe AS, Vervaet A, Dobbeleir A, et al. Prediction of functional outcome by quantification of sestamibi and BMIPP after acute myocardial infarction. Eur J Nucl Med, 2000, 27(10): 1494-1500. doi: 10.1007/s002590000332 [16] Nakata T, Hashimoto A, Eguchi M. Cardiac BMIPP imaging in acute myocardial infarction. Int J Card Imaging, 1999, 15(1): 21-26. [17] Fukuchi K, Hasegawa S, Ito Y, et al. Detection of coronary artery disease by iodine-123-labeled iodophenyl-9-methyl pentadecanoic acid SPECT: comparison with thallium-201 and iodine-123 BMIPP SPECT. Ann Nucl Med, 2000, 14(1): 11-16. [18] Fukushima Y, Toba M, Ishihara K, et al. Usefulness of 201TlCl/123I-BMIPP dual-myocardial SPECT for patients with non-ST segment elevation myocardial infarction. Ann Nucl Med, 2008, 22(5): 363-369. [19] Nakata T, Kobayashi T, Tamaki N, et al. Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction. Nucl Med Commun, 2000, 21(10): 897-906. [20] Ito T, Tanouchi J, Kato J, et al. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on 123I-BMIPP and 201Tl SPET images. Eur J Nucl Med, 1996, 23(8): 917-923. doi: 10.1007/BF01084365 [21] Hambye AS, Vervaet A, Dobbeleir A. Quantification of 99Tcm-sestamibi and 123I-BMIPP for predicting functional outcome in chronically dysfunctional myocardium. Nucl Med Commun, 1999, 20(8): 737-745. doi: 10.1097/00006231-199908000-00008 [22] Geeter FD, Franken PR, Defrise M, et al. Optimal collimator choice for sequential iodine-123 and technetium-99m imaging. Eur J Nucl Med, 1996, 23(7): 768-774. [23] Mochizuki T, Murase K, Higashino H, et al. Ischemic "memory image" in acute myocardial infarction of 123I-BMIPP after reperfusion therapy: a comparison with 99mTc-pyrophosphate and 201Tl dual-isotope SPECT. Ann Nucl Med, 2002, 16(8): 563-568. doi: 10.1007/BF02988634 [24] Amano Y, Kumita S, Takayama M, et al. Comparison of contrast-enhanced MRI with Iodine-123 BMIPP for detection of myocardial damage in hypertrophic cardiomyopathy. AJR Am J Roentgenol, 2005, 185(2): 312-318. doi: 10.2214/ajr.185.2.01850312 [25] Narita M, Kurihara T. Is I-123-beta-methyl-p-iodophenylmethyl pentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy. Int J Cardiovasc Imaging, 2003, 19(6): 499-510. doi: 10.1023/B:CAIM.0000004262.48898.5d [26] Narita M, Kurihara T, Sindoh T, et al. Successive myocardial fatty acid metabolic imaging in patient with dilated cardiomyopathy: usefulness as a prognostic indicator. Kaku Igaku, 2000, 37(4): 303-310. [27] Inoue A, Fujimoto S, Yamashina S, et al. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Ann Nucl Med, 2007, 21(7): 399-404. doi: 10.1007/s12149-007-0045-8 [28] Nakata T, Kobayashi T, Tamaki N, et al. Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction. Nucl Med Commun, 2000, 21(10): 897-907. doi: 10.1097/00006231-200010000-00003 [29] Matsuki T, Tamaki N, Nakata T, et al. Prognostic value of fatty acid imaging in patients with angina pectoris without prior myocardial infarction: comparison with stress thallium imaging. Eur J Nucl Med Mol Imaging, 2004, 31(12): 1585-1591. doi: 10.1007/s00259-004-1551-8 [30] Inaba Y, Bergmann SR. Prognostic value of myocardial metabolic imaging with BMIPP in the spectrum of coronary artery disease: A systemic review. J Nucl Cardiol, 2010, 17(1): 61-70. doi: 10.1007/s12350-009-9157-y [31] Nishimura M, Hashimoto T, Kobayashi H, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int, 2004, 66(2): 811-829. doi: 10.1111/j.1523-1755.2004.00808.x [32] Nishimura M, Hashimoto T, Kobayashi H, et al. Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. Kidney Int, 2004, 66(2): 811-829. Nishimura M, Tsukamoto K, Hasebe N, et al. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol, 2008, 51(2): 139-145. doi: 10.1111/j.1523-1755.2004.00808.x [33] Nishimura M, Tokoro T, Nishida M, et al. Prediction of cardiac death after coronary revascularization by myocardial fatty acid imaging in hemodialysis patients. Kidney Int, 2008, 74(4): 513-520. doi: 10.1038/ki.2008.211
计量
- 文章访问数: 1833
- HTML全文浏览量: 1051
- PDF下载量: 3